/ /

  • linkedin
  • Increase Font
  • Sharebar

    ACIP updates vaccination guidelines for 2016

    Changes to vaccination protocols against meningococcal serotype B (MenB) and human papillomavirus (HPV) are some of the most significant in the 2016 immunization schedule released recently by the Advisory Committee on Immunization Practices (ACIP), a branch of the Centers for Disease Control and Prevention (CDC).

    The new schedule has been endorsed by a number of medical groups including the American College of Obstetricians and Gynecologists, the American Academy of Family Physicians, and the American Academy of Pediatrics (AAP). The immunization schedule is revised annually.

    More: When 'firing' a patient for vaccine refusal is the only response

    “Changes in the child/adolescent schedule reflect new ACIP recommendations and provide additional information on existing recommendations,” says Candice L Robinson, MD, MPH, of United States Public Health Service and the CDC’s National Center for Immunization and Respiratory Diseases. “The purpose of the recommended immunization schedule is to protect infants and children by providing immunity early in life, before they are exposed to potentially life-threatening diseases. Healthcare professionals are the greatest source of vaccine information for patients and parents. We encouraged them to stay up-to-date on the latest ACIP recommendations.”

    Robinsons says the new MenB vaccine recommendation now applies to groups that are not normally considered high-risk—healthy individuals aged 16 to 18 years—plus anyone aged older than 10 years that may face increased risks of developing the disease, including children with sickle cell disease or other immune problems.

    Meningococcal serotype B attacks the lining of the brain and the spinal cord, and causes death in 10% of cases and permanent disability in 14% of cases. This particular strain accounts for about one-third of the meningitis cases in the United States, according to CDC.

    Two MenB vaccines are available—Trumemba and Bexsero. The ACIP advised that either vaccine could be used, but they should not be interchanged once the vaccination series begins.

    The change in the recommendation on the HPV vaccine reflects recent guidance from various medical groups over the last year, following the US Food and Drug Administration’s approval of 9-valent HPV vaccine (9vHPV), which protects against 9 types of HPV.

    Two other formulations of the vaccine—2-valent HPV and 4-valent HPV—are also available, but do not protect against as many strains of the virus. These vaccines cover strains responsible for about 66% of HPV cases, while the 9vHPV vaccine covers additional strains that are responsible for 14% of HPV cancers in females and 4% in males, according to CDC.

    “The new vaccine covers 9 strains of HPV, offering protection against at least 80% of the cervical, vulvar and anal cancers caused by HPV,” AAP writes in a statement on the new vaccine schedule. “The schedule continues to recommend HPV vaccination beginning at age 11 years, but it now advises that because children with a history of sexual abuse are at increased risk of HPV, the first dose should be administered at age 9 years.”

    NEXT: What else has changed?

    Rachael Zimlich, RN
    Rachael Zimlich is a freelance writer in Cleveland, Ohio. She writes regularly for Contemporary Pediatrics, Managed Healthcare ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    Latest Tweets Follow